The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years. With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

The pre-eminent reference on coagulation disorders is now in its thoroughly updated Fifth Edition. Written by more than 160 of the world's foremost authorities, this encyclopedic volume integrates basic science and clinical practice and details all that is currently known about blood clotting disorders and how to manage patients with these and related problems. This edition has been reorganized into smaller, more tightly focused chapters to help readers find information easily. A new co-editor, Samuel Z. Goldhaber, MD, has expanded the cardiology portion of the book. Other new features include a two-color page design and more than 100 full-color illustrations.